These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12242147)

  • 21. Overcoming immune evasion in T cell therapy of cancer: lessons from animal models.
    Liu JQ; Bai XF
    Curr Mol Med; 2008 Feb; 8(1):68-75. PubMed ID: 18289015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor microenvironment and immune escape.
    Ferrone S; Whiteside TL
    Surg Oncol Clin N Am; 2007 Oct; 16(4):755-74, viii. PubMed ID: 18022543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumors hijack fetal enzyme, escape killer T cells.
    Schepers K; Schumacher TN
    Nat Med; 2003 Oct; 9(10):1253-4. PubMed ID: 14520367
    [No Abstract]   [Full Text] [Related]  

  • 24.
    Scorpio DG; Choi KS; Dumler JS
    Front Immunol; 2018; 9():710. PubMed ID: 29686681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Emerging Role of CD8
    Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
    Front Immunol; 2018; 9():1904. PubMed ID: 30158938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay.
    Kim GG; Donnenberg VS; Donnenberg AD; Gooding W; Whiteside TL
    J Immunol Methods; 2007 Aug; 325(1-2):51-66. PubMed ID: 17617419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Innate Immunity Protein Tag7 Induces 3 Distinct Populations of Cytotoxic Cells That Use Different Mechanisms to Exhibit Their Antitumor Activity on Human Leukocyte Antigen-Deficient Cancer Cells.
    Sharapova TN; Ivanova OK; Soshnikova NV; Romanova EA; Sashchenko LP; Yashin DV
    J Innate Immun; 2017; 9(6):598-608. PubMed ID: 28977785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New insights into cytotoxic effector cells].
    Rey J; Olive D; Sébahoun G; O'Callaghan T; Costello RT
    Bull Cancer; 2005 Nov; 92(11):935-43. PubMed ID: 16316827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
    Dong H; Strome SE; Salomao DR; Tamura H; Hirano F; Flies DB; Roche PC; Lu J; Zhu G; Tamada K; Lennon VA; Celis E; Chen L
    Nat Med; 2002 Aug; 8(8):793-800. PubMed ID: 12091876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma.
    Wang E; Selleri S; Marincola FM
    Clin Cancer Res; 2007 Dec; 13(24):7228-31. PubMed ID: 18094399
    [No Abstract]   [Full Text] [Related]  

  • 31. NKT cells and tumor immunity--a double-edged sword.
    Smyth MJ; Godfrey DI
    Nat Immunol; 2000 Dec; 1(6):459-60. PubMed ID: 11101862
    [No Abstract]   [Full Text] [Related]  

  • 32. Tumor escape from killing: role of killer inhibitory receptors and acquisition of tumor resistance to cell death.
    Chouaib S; Thiery J; Gati A; Guerra N; El Behi M; Dorothée G; Mami-Chouaib F; Bellet D; Caignard A
    Tissue Antigens; 2002 Oct; 60(4):273-81. PubMed ID: 12472656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of T lymphocytes in the immunotherapy of tumours.
    Brondz BD; Balashov KE
    Biomed Sci; 1991; 2(5):441-9. PubMed ID: 1840832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How Do Cytotoxic Lymphocytes Kill Cancer Cells?
    Martínez-Lostao L; Anel A; Pardo J
    Clin Cancer Res; 2015 Nov; 21(22):5047-56. PubMed ID: 26567364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Uric acid enhances the antitumor immunity of dendritic cell-based vaccine.
    Wang Y; Ma X; Su C; Peng B; Du J; Jia H; Luo M; Fang C; Wei Y
    Sci Rep; 2015 Nov; 5():16427. PubMed ID: 26553557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of human circulating and tumor-infiltrating lymphocytes in cancer defense and treatment.
    Lotzová E
    Nat Immun Cell Growth Regul; 1990; 9(4):253-64. PubMed ID: 2215514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
    Braza MS; Klein B
    Br J Haematol; 2013 Jan; 160(2):123-32. PubMed ID: 23061882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of Cytotoxic Lymphocyte-Mediated Apoptosis and Relationship with the Tumor Suppressor p53.
    Thiery J; Safta TB; Ziani L; Chouaib S
    Crit Rev Immunol; 2015; 35(6):433-49. PubMed ID: 27279042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of CD8+ T lymphocytes that persist after peripheral tolerance to a self antigen expressed in the pancreas.
    Nugent CT; Morgan DJ; Biggs JA; Ko A; Pilip IM; Pamer EG; Sherman LA
    J Immunol; 2000 Jan; 164(1):191-200. PubMed ID: 10605011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.